Buscar
Congreso SOLACI

Artículos del autor

Dr. Omar Tupayachi

Member of the Editorial Board of solaci.org
Other

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an...
Dr. Omar Tupayachi -
Structural heart disease

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the...
Dr. Omar Tupayachi -
Structural heart disease

COMPARE TAVI: One-Year Results of a Randomized Study Comapring Two Balloon-Expandable Valves

The COMPARE TAVI organization conducted direct comparison of new transcatheter aortic valve implantation (TAVI) devices against contemporary...
Dr. Omar Tupayachi -
Pharmacology

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular...
Dr. Omar Tupayachi -
Coronary Disease

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in...
Dr. Omar Tupayachi -
Coronary Disease

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated...
Dr. Omar Tupayachi -
Structural heart disease

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher...
Dr. Omar Tupayachi -
Iliac

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as...
Dr. Omar Tupayachi -

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Dr. Juan Manuel Pérez - 0
Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Dr. Juan Manuel Pérez - 0
Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

Dr. Omar Tupayachi - 0
The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Noticias Institucionales

How to apply for the SOLACI Research 2025 Grant? Step-by-step explanation video

solaci - 0
You can now rewatch the virtual event we held on April 9th, where we thoroughly reviewed the steps to apply for the SOLACI Research...

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad